Is the price fair?
What NBIX's price assumes
Neurocrine Biosciences, Inc. trades at 24.1× earnings against 24.4× for the median Drug Manufacturers - Specialty & Generic name, cheaper than its own group.
24.1
Trailing P/E · Drug Manufacturers - Specialty & Generic median 24.4 · cheaper than the typical name in its group
- Price / sales
- 4.39
Price / sales · as of 2026-Q1
- Free cash flow yield
- 5.2%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.5%
- Growth the price implies
- +5.1%
Growth the price implies · The price pays for +5.1% free cash flow growth a year for a decade; the business has delivered +52% a year over the last three.
Details›
- Price / book2026-Q1
- 4.00
- Healthcare median P/E362 names
- 31.5
- Drug Manufacturers - Specialty & Generic median P/E32 names
- 24.4
- Free cash flow, trailing twelve months
- $827M
- Market capitalisation
- $15.9B
- 3-year revenue growth
- +25%
- 3-year free cash flow growth
- +52%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $243.50 |
| Its own P/E history, median | $275.97 |
| Its own P/E history, upper quartile | $365.82 |
| 52-week range | $123.10 – $182.85 |
| Today | $156.58 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - Specialty & Generic
Ranks #8 of 28 by Smart Score